Argenx (ARGX)
(Delayed Data from NSDQ)
$379.30 USD
+3.49 (0.93%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $379.34 +0.04 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
argenex SE [ARGX]
Reports for Purchase
Showing records 41 - 60 ( 280 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Don''t Forget About gMG; 2Q23 Vyvgart Sales Beat Again
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Hytrulo?s Value Proposition in CIDP Looks Like a Game-Changer; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Nothing Sticky About This Wicket, ADHERE''s a Success
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Takeaways From KOL Dinner Event on Navigating the anti-FcRn Competitive LandscapeThis report contains brief updates on the following: ARGX, IMVT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Welcomes a Newcomer to the gMG Arena
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Additional Perspectives After Vyvgart Hytrulo Approval; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
SubQ Efgartigimod Approval Arrives and ARGX-117 Provides Early Efficacy Signal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Biotechnology- EHA 2023 Roundup for Covered Companies (Part 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation with argenx?s Chief Scientific Officer; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
EHA 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D